All Substitutes


Loading...

Disclaimer

Want to know more?
Read Our Editorial Policy

Did you find this information helpful?

    
REVOLADE 25MG TABLET_1
REVOLADE 25MG TABLET_2
REVOLADE 25MG TABLET_1
10% Off

Revolade 25mg Tablet

Prescription Required

Salt Composition : Eltrombopag

Manufacturer : NOVARTIS INDIA LTD

Origin of Medicine : India

MRP: 15194
Price : 13675
You Save : 1519 (10%)

14 Tablet(s) In A Box

PAP Information :    Contact us for latest updates.

Pincode
Delivery By -

Patient Assistance Programs
Know About PAP

Program Overview: NOVARTIS INDIA LTD Patient Assistance Program (PAP) is dedicated to helping patients in need of Revolade 25 mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.

Program Benefits: Patient assistance programs (PAPs) are sponsored by pharmaceutical companies and are an important step towards lowering overall therapy costs for patients. The purpose of these initiatives is to provide financial assistance to patients so they can obtain drugs at low or no cost. MrMed will guide you through the procedure and ensure you receive your PAP medication correctly. 

Contact us for the latest updates on this exclusive offer.

Eligibility Criteria: To qualify for the Revolade 25 mg tablet Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Eltrombopag from a physician and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.

Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].

Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Novartis India Ltd can avail of it without having to purchase the medication from MrMed.

Patient Assistance Programs

Program Overview: NOVARTIS INDIA LTD Patient Assistance Program (PAP) is dedicated to helping patients in need of Revolade 25 mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.

Program Benefits: Patient assistance programs (PAPs) are sponsored by pharmaceutical companies and are an important step towards lowering overall therapy costs for patients. The purpose of these initiatives is to provide financial assistance to patients so they can obtain drugs at low or no cost. MrMed will guide you through the procedure and ensure you receive your PAP medication correctly. 

Contact us for the latest updates on this exclusive offer.

Eligibility Criteria: To qualify for the Revolade 25 mg tablet Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Eltrombopag from a physician and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.

Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].

Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Novartis India Ltd can avail of it without having to purchase the medication from MrMed.

Introduction to Revolade 25mg Tablet

Revolade 25mg tablet is an anticoagulant drug belonging to the thrombopoietin (TPO) receptor agonist category, containing the active ingredient Eltrombopag. It treats low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection. ITP refers to an autoimmune disorder in which the immune system destroys platelets. Platelets are blood cells that aid in clotting and protect blood vessel walls. When platelet levels are low, it can result in severe bleeding and bruising. This tablet is also used in adults to treat low blood counts caused by severe aplastic anaemia (a serious blood disease that occurs when the bone marrow fails to produce enough new blood cells).

This drug should not be used in individuals with known hypersensitivity or allergic reactions to the drug or its components. Allergic reactions can range from mild to severe and may include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Revolade 25mg tablets are contraindicated in patients with severe liver impairment or active liver disease. This drug can potentially cause hepatotoxicity, as increased liver enzymes and bilirubin levels indicate. Using this drug in individuals with severe liver disease can further worsen liver function, so caution is advised. Your doctor will recommend that you are checked for cataracts. Your doctor should arrange regular testing if you do not have routine eye tests. You may also be checked for bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye).

If you stop taking this tablet, your blood platelet count is likely to become low again within several days. The platelet count will be monitored, and your doctor will discuss appropriate precautions. A very high blood platelet count may increase the risk of blood clotting. However, blood clots can also form with normal or even low platelet counts. Your doctor will adjust your dose of this medicine to ensure that your platelet count does not become too high. Do not take this tablet with dairy products or drinks, as the calcium in these items affects the absorption of the medicine. Use effective birth control during the treatment, and if you become pregnant, you must inform your doctor. Revolade 25mg tablets are not advised for children under one with ITP. It is also not recommended for patients under 18 with low platelet counts caused by hepatitis C or severe aplastic anaemia. Tell your doctor if you are taking, have recently taken, or might take other medicines. It includes medicines obtained without a prescription and vitamins.


Uses of Revolade 25mg Tablet

Revolade 25mg tablet is used to treat,

  • Low platelet counts are caused by primary immune thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.
  • Severe aplastic anemia

Therapeutic Effects of Revolade 25mg Tablet

Revolade 25mg tablets stimulate megakaryocytes (the large bone marrow cells) responsible for producing platelets. By raising the number of platelets in the blood, this drug prevents bleeding and bruising.


Interaction of Revolade 25mg Tablet with other drugs

Inform your healthcare provider about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications include antacid medicines, statins, ciclosporin, methotrexate, topotecan, lopinavir, or ritonavir, and vitamin and mineral supplements may interact with Revolade 25mg Tablet and reduce effectiveness by causing undesirable side effects. 


More Information about Revolade 25mg Tablet

  • Store Revolade 25mg Tablet at room temperature (25°C).
  • Keep the medicine out of reach of children and pets.

How to consume Revolade 25mg Tablet

It is an orally available prescription drug. Your doctor will decide the dose and duration of the drug based on the disease condition and other factors. Always take an Revolade 25mg Tablet as prescribed by your doctor. Take the tablet with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water.


Safety Advices for Revolade 25mg Tablet

Image Not Available  

Pregnancy

  

Revolade 25mg Tablet is not recommended for pregnant patients because it may cause fetal harm. You must inform your doctor if you are pregnant, suspecting, or planning to get pregnant during the treatment.

Image Not Available  

Breast Feeding

  

It is not known whether Revolade 25mg Tablet passes into breast milk. If you are breastfeeding or planning to breastfeed, tell your doctor.

Image Not Available  

Lungs

  

It is unknown whether Revolade 25mg Tablet can be prescribed for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.

Image Not Available  

Liver

  

Revolade 25mg Tablet should be cautiously administered in patients with severe liver diseases. Dose adjustments are necessary for severe liver failure. Inform your doctor if you have liver issues before initiating the therapy.

Image Not Available  

Alcohol

  

It is unknown whether alcohol may interact with the Revolade 25mg Tablet. Inform your physician if you drink alcoholic beverages.

Image Not Available  

Driving

  

Driving vehicles or operating heavy machinery is unsafe after taking the Revolade 25mg Tablet. It may cause dizziness and impair concentration.


Side Effects of Revolade 25mg Tablet

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Common

  • Nausea
  • Diarrhea, abdominal pain
  • Common cold
  • Cough
  • Respiratory tract infection
  • Back pain
  • High temperature, cough
  • Loss of appetite
  • Hair loss
  • Swelling in feet or hands
  • Headache, dizziness
  • Mouth and throat pain
  • Joint pain

Word of Advice

Ensure that in the 2 hours after or 4 hours before you take this medication, you don’t consume dairy foods (such as cheese or butter), milk or milkshakes, antacids, and supplements containing iron, aluminum, magnesium, calcium, selenium, zinc, or calcium. If you forget to take the Revolade 25mg tablet, take your next dose at the usual time. Do not take more than one dose of this drug daily. Don’t stop taking this tablet without talking to your doctor. If your doctor advises you to stop treatment, your platelet count will be checked each week for four weeks. If you have any doubts regarding the use of this medicine, ask your doctor.


FAQs

Q 1. What is ITP?

Immune thrombocytopenia, also known as ITP, is a rare blood disorder. People with ITP have insufficient platelets in their blood. A low platelet count can cause bruising and bleeding.

Q 2. Who should not use the Revolade 25mg tablet?

People with immune (primary thrombocytopenia (ITP) and children under one should not use Revolade 25mg tablets. It is also not suggested for people with severe aplastic anemia and hepatitis C.

Q 3. Will you be monitored during treatment with the Revolade 25mg tablet?

Yes, you will be monitored during the Revolade 25mg tablet. Your healthcare provider will regularly access your white blood cell, platelets, blood clotting factors, heart rate, eye test, and complete blood count.

Q 4. Is it safe to take a Revolade 25mg tablet on an empty stomach?

Yes, Revolade 25mg tablets should be taken on an empty stomach. Because antacids, mineral and vitamin supplements (iron, calcium, magnesium, aluminum, selenium, and zinc), dairy products, calcium-enriched foods, and fortified juices interfere with this drug absorption. So, please take them at least two hours before or four hours after taking the medication.

Q 5. What happens if you discontinue using the Revolade 25mg tablet?

If you discontinue using Revolade 25mg tablets suddenly, it decreases platelet count as it can lead to severe bleeding. However, telling your healthcare practitioner before discontinuing this medication is advisable.

Q 6. How to store a Revolade 25mg tablet?

Store Revolade 25mg tablet at 25°C and out of the reach of children. After the expiration date, do not use this medication.


Fact Box of Revolade 25mg Tablet

Molecule name: EltrombopagTherapeutic class: Anticoagulant
Pharmacological class: Thrombopoietin (TPO) receptor agonist

Indications: 

1. Low platelet counts caused by immune primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.

2. Severe aplastic anaemia.


References

  1. Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on Jan 2022] [Accessed on 22 May 2023], https://www.medicines.org.uk/emc/files/pil.508.pdf
  2. GlaxoSmithKline, US Food and Drug Administration, [ Revised on October 2008] [Accessed on 22 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf
  3. Revolade, Annex I summary of Product Characteristics - European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf [Accessed on 22 May 2023].

Disclaimer

MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.